InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

EXOZYMES INC.

EXOZ Clue Score20
United States Fiscal year ends December CIK 0002010788
$5.25 -0.38% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $5.25 −61.11% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 13 Nov 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue0.1Operating income−1.8Net income−2.0EPS, diluted−0.33Fiscal year 2024Operating income−5.9Net income−5.9EPS, diluted−0.89Fiscal year 2025Operating income−9.7Net income−9.2EPS, diluted−1.09
FY2023FY2024FY2025
Revenue 0.1 n/a n/a
Growth
Operating income −1.8 −5.9 −9.7
Net income −2.0 −5.9 −9.2
Growth
EPS, diluted −0.33 −0.89 −1.09
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin−2,563.5%Net margin−2,909.1%Free cash flow margin−2,097.3%Fiscal year 2024Fiscal year 2025
FY2023FY2024FY2025
Operating margin −2,563.5% n/a n/a
Net margin −2,909.1% n/a n/a
Free cash flow margin −2,097.3% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−1.2Capital expenditure−0.3Free cash flow−1.5Fiscal year 2024Operating cash flow−8.5Capital expenditure−0.4Free cash flow−8.9Fiscal year 2025Operating cash flow−6.5Capital expenditure−0.2Free cash flow−6.7
FY2023FY2024FY2025
Operating cash flow −1.2 −8.5 −6.5
Capital expenditure −0.3 −0.4 −0.2
Free cash flow −1.5 −8.9 −6.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.1Shareholders’ equity−0.4Fiscal year 2024Cash9.7Shareholders’ equity10.4Fiscal year 2025Cash3.0Shareholders’ equity3.4
FY2023FY2024FY2025
Cash 0.1 9.7 3.0
Shareholders’ equity −0.4 10.4 3.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.1 n/a n/a
Growth
0.5 1.9 3.7
1.3 4.1 6.0
−1.8 −5.9 −9.7
Growth
−2.0 −5.9 −9.3
0.0 n/a −0.1
−2.0 −5.9 −9.2
Growth
Per share
−0.33 −0.89 −1.09
−0.33 −0.89 −1.09
Growth
6.3 6.6 8.4
6.3 6.6 8.4
Growth +5.0% +27.7%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.